{"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"groups":[{"description":"Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate: Weeks 1-15:\n\n* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days\n* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle\n* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\\&5 of R-CHOP\n\nWeeks 18-22:\n\n• Methotrexate 1.5 g/m2 q14 Days x 2\n\nFrom Week 24:\n\n• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)","id":"BG000","title":"R-CHOP, Depocyte, Methotrexate"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"37","upperLimit":"79","value":"66"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"54"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"title":"Switzerland"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Stage II"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"description":"Ann Arbor staging is the staging system for lymphomas. The stage depends on the place where the malignant tissue is located.\n\n* Stage I indicates that the cancer is located in a single region, usually one lymph node and the surrounding area.\n* Stage II indicates that the cancer is located in two separate regions, an affected lymph node or lymphatic organ and a second affected area, both affected areas are confined to one side of the diaphragm.\n\nStage II indicates a worse outcome.","paramType":"COUNT_OF_PARTICIPANTS","title":"Ann Arbor stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Bilateral testicular location"},{"measurements":[{"groupId":"BG000","value":"53"}],"title":"No bilateral testicular location"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Bilateral testicular location","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Presence of B symptoms"},{"measurements":[{"groupId":"BG000","value":"52"}],"title":"No Presence of B symptoms"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"description":"B symptoms include fever, night sweats and weight loss of ≥10% of body weight over 6 months. Presence of B symptoms indicates a worse outcome.","paramType":"COUNT_OF_PARTICIPANTS","title":"B symptoms","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}],"title":"> normal upper value"},{"measurements":[{"groupId":"BG000","value":"47"}],"title":"</= normal upper value"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Serum lactate dehydrogenase (LDH)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"> normal upper value"},{"measurements":[{"groupId":"BG000","value":"40"}],"title":"</= normal upper value"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Not recorded"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Serum Beta2-microglobulin","unitOfMeasure":"Participants"}]}